RCKT (Rocket Pharmaceuticals) Cyclically Adjusted Book per Share: $7.26 (As of Mar. 2026)


RCKT Rocket Pharmaceuticals Inc RCKT
30 GF Score
Price $3.84
! 3 Warning Signs
View Full Analysis

What is Rocket Pharmaceuticals Cyclically Adjusted Book per Share?

Rocket Pharmaceuticals RCKT +9.25% 30 Cyclically Adjusted Book per Share is $7.26 as of Mar. 2026. GuruFocus rates RCKT with a GF Score™ of 30/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Rocket Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was $2.181. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $7.26 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Rocket Pharmaceuticals's average Cyclically Adjusted Book Growth Rate was -13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-04), Rocket Pharmaceuticals's current stock price is $3.84. Rocket Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $7.26. Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 0.53.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rocket Pharmaceuticals was 0.53. The lowest was 0.00. And the median was 0.00.


Rocket Pharmaceuticals  (NAS:RCKT) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=3.84/7.26
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Rocket Pharmaceuticals was 0.53. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Rocket Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Rocket Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Rocket Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals Cyclically Adjusted Book per Share Chart

Rocket Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 7.98 8.74 7.58

Rocket Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.67 8.57 8.10 7.58 7.26

RCKT vs TENX, DMAC, AVIR: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


RCKT
30GF Score
Rocket Pharmaceuticals Inc RCKT
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rocket Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rocket Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.181/330.2130*330.2130
=2.181

Current CPI (Mar. 2026) = 330.2130.

Rocket Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 14.176 241.018 19.422
201609 12.632 241.428 17.277
201612 10.845 241.432 14.833
201703 9.377 243.801 12.701
201706 8.519 244.955 11.484
201709 7.504 246.819 10.039
201712 7.018 246.524 9.400
201803 4.318 249.554 5.714
201806 3.976 251.989 5.210
201809 3.605 252.439 4.716
201812 4.293 251.233 5.643
201903 3.925 254.202 5.099
201906 4.937 256.143 6.365
201909 4.606 256.759 5.924
201912 5.611 256.974 7.210
202003 5.189 258.115 6.638
202006 4.831 257.797 6.188
202009 4.381 260.280 5.558
202012 8.255 260.474 10.465
202103 7.743 264.877 9.653
202106 7.714 271.696 9.375
202109 7.536 274.310 9.072
202112 7.049 278.802 8.349
202203 6.473 287.504 7.435
202206 5.889 296.311 6.563
202209 5.414 296.808 6.023
202212 6.189 296.797 6.886
202303 5.707 301.836 6.244
202306 5.005 305.109 5.417
202309 6.002 307.789 6.439
202312 5.456 306.746 5.873
202403 4.871 312.332 5.150
202406 4.229 314.175 4.445
202409 3.619 315.301 3.790
202412 4.351 315.605 4.552
202503 3.861 319.799 3.987
202506 3.283 322.561 3.361
202509 2.899 324.800 2.947
202512 2.559 324.054 2.608
202603 2.181 330.213 2.181

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $7.26 mean?
Rocket Pharmaceuticals (RCKT) has a Cyclically Adjusted Book per Share of $7.26 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rocket Pharmaceuticals and its competitors.
Is Rocket Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Rocket Pharmaceuticals' current Cyclically Adjusted Book per Share is $7.26. Overall, Rocket Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Rocket Pharmaceuticals' Cyclically Adjusted Book per Share compare to TENX and DMAC?
Rocket Pharmaceuticals' Cyclically Adjusted Book per Share of $7.26 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Rocket Pharmaceuticals and its competitors. Rocket Pharmaceuticals's current Cyclically Adjusted Book per Share is $7.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rocket Pharmaceuticals stock overvalued right now?
Rocket Pharmaceuticals (RCKT) has a current Cyclically Adjusted Book per Share of $7.26. The current Cyclically Adjusted Book per Share is $7.26. Rocket Pharmaceuticals' overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Rocket Pharmaceuticals (RCKT), the current Cyclically Adjusted Book per Share is $7.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rocket Pharmaceuticals Business Description

Other Exchanges 9IP1:Germany
Address 9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
30GF Score

Get the complete analysis for RCKT

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.84
Price